NewsHK
StockStory identifies three healthcare stocks that investors should avoid due to regulatory risks and fundamental weaknesses, despite the sector outperforming the S&P 500 by 21.7 percentage points over the past six months.
The healthcare industry has posted a 31.4% gain during this period, but the outlet cautions that heavy regulation can influence earnings potential for many businesses in the space.
Integra LifeSciences, a regenerative medicine pioneer founded in 1989, has a market capitalization of $1.05 billion. The company develops medical technologies for neurosurgery, wound care, and surgical reconstruction.
StockStory flags concerns regarding Integra's organic revenue growth, which has fallen short of benchmarks over the past two years, suggesting a need to improve products, pricing, or go-to-market strategy.
Keep reading